Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer

Next Previous
Trial Profile

A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil/Caelyx) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Technetium Tc99m etarfolatide (Primary) ; Vintafolide (Primary) ; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Acronyms PROCEED
  • Sponsors Endocyte; Merck Sharp & Dohme

    • Most Recent Events

    • 24 Sep 2021 Status changed from suspended to discontinued as per DSMB decision.
    • 27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
    • 20 Mar 2015 Results will be presented at the 2015 Annual Meeting on Women's Cancer in Chicago in March 2015, according to an Endocyte media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top